Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b/3 randomized, double-blind, sham-controlled trial of VTS-270 in Niemann-Pick type C1 (NPC1) disease
2015-002548-15Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Sep 2015
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Trappsol Cyclo in Niemann-Pick disease type C1 (NPC1) (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Dose selection based on safety and tolerability (including audiologic evaluation). Started Sep 2015; status: completed.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C1 (NPC1)
Beyond the preview
Go deeper on 2015-002548-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002548-15.